Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Agile Therapeutics, Inc. (Nasdaq: AGRX) will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 9:10 a.m. ET. The conference will be held virtually, allowing broader access for participants.
A live webcast of the presentation will be available on Agile's Investor Relations page, and an archived version will remain accessible for 30 days. Agile focuses on women's healthcare and offers contraceptive solutions via its Twirla® transdermal system, allowing women flexibility in their contraceptive choices without the need for daily pills.
Details
News Market Reaction – AGRX
The recorded move for AGRX in the trading session of this news was +1.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on Thursday, January 14, 2021, at 9:10 a.m. ET.
A live webcast of the presentation will be available in the Events and Presentations section of the Agile Therapeutics Investor Relations page. The archived webcast will be available for 30 days.
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.
Follow Agile on LinkedIn and Twitter: @AgileTher.
Contact:
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.